Prostate diseases - Role of sex steroids and their inhibitors

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 2, 2011, Pages 355-367

  Welén, Karin ^a   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

5 reductase; Androgen receptor; Benign prostate hyperplasia; DHT; Prostate; Prostate cancer; Steroid metabolism; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; CHOLESTENONE 5ALPHA REDUCTASE; DUTASTERIDE; DUTASTERIDE PLUS TAMSULOSIN; FINASTERIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PLACEBO; TAMSULOSIN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CASTRATION; GENERAL PRACTICE; HUMAN; PARACRINE SIGNALING; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; ANDROGENS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 79952550843     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2010.09.008     Document Type: Review

References (114)

1. McVary KT. BPH: epidemiology and comorbidities. The American Journal of Managed Care 2006; 12(Suppl. 5): S122-S128.
2. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005; 55(2): 74-108.
3. Boyle P & Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals of Oncology 2005; 16(3): 481-488.
4. Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8(3): 439-443.
5. Ferlay J, Parkin DM & Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2010; 46(4): 765-781.
6. *6. Damber JE & Aus G. Prostate cancer. Lancet 2008; 371(9625): 1710-1721.
7. Takeda H & Chang C. Immunohistochemical and in-situ hybridization analysis of androgen receptor expression during the development of the mouse prostate gland. The Journal of Endocrinology 1991; 129(1): 83-89.
8. Cooke PS, Young P & Cunha GR. Androgen receptor expression in developing male reproductive organs. Endocrinology 1991; 128(6): 2867-2873.
9. Wikstrom P, Marusic J, Stattin P et al. Low stroma androgen receptor level in normal and tumour prostate tissue is related to poor outcome in prostate cancer patients. The Prostate 2009; 69(8): 799-809.
10. Prins GS, Birch L & Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991; 129(6): 3187-3199.
11. Godoy A, Watts A, Sotomayor P et al. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 2008; 149(6): 2959-2969. (Pubitemid 351724500)
12. Cunha GR, Hayward SW, Wang YZ et al. Role of the stromal microenvironment in carcinogenesis of the prostate. International Journal of Cancer 2003; 107(1): 1-10.
13. Iwamura M, Abrahamsson PA, Benning CM et al. Androgen receptor immunostaining and its tissue distribution in formalin-fixed, paraffin-embedded sections after microwave treatment. The Journal of Histochemistry and Cytochemistry 1994; 42(6): 783-788. (Pubitemid 24159889)
14. Kimura N, Mizokami A, Oonuma T et al. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. The Journal of Histochemistry and Cytochemistry 1993; 41(5): 671-678. (Pubitemid 23118737)
15. English HF, Santen RJ & Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. The Prostate 1987; 11(3): 229-242. (Pubitemid 18004762)
16. Bonkhoff H, Stein U & Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Archiv. A, Pathological Anatomy and Histopathology 1993; 423(4): 291-294.
17. Wright AS, Douglas RC, Thomas LN et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 1999; 140(10): 4509-4515. (Pubitemid 30666115)
18. Deslypere JP, Young M, Wilson JD et al. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Molecular and Cellular Endocrinology 1992; 88(1-3): 15-22.
19. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumour growth. Cancer Research 2008; 68(11): 4447-4454.
20. Pelletier G, Luu-The V, Huang XF et al. Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. The Journal of Urology 1998; 160(2): 577-582. (Pubitemid 29476737)
21. Titus MA, Gregory CW, Ford 3rd OH et al. Steroid 5 alpha-reductase isozymes I and II in recurrent prostate cancer. Clinical Cancer Research 2005; 11(12): 4365-4371. (Pubitemid 40825625)
22. Uemura M, Tamura K, Chung S et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormonerefractory prostate cancer. Cancer Science 2008; 99(1): 81-86. (Pubitemid 350239034)
23. Iehle C, Radvanyi F, Gil Diez de Medina S et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. The Journal of Steroid Biochemistry and Molecular Biology 1999; 68(5-6): 189-195. (Pubitemid 29290654)
24. O'Malley KJ, Dhir R, Nelson JB et al. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. The Prostate 2009; 69(16): 1716-1723.
25. Bauman DR, Steckelbroeck S, Peehl DM et al. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 2006; 147(12): 5806-5816. (Pubitemid 44833497)
26. Geller J & Albert J. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urological Research 1987; 15(3): 151-153.
27. Carson 3rd C & Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61(4 Suppl.1): 2-7. (Pubitemid 36349123)
28. Marcelli M & Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. The Journal of Clinical Endocrinology and Metabolism 1999; 84(10): 3463-3468. (Pubitemid 30645192)
29. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. The New England Journal of Medicine 1998; 338(9): 557-563. (Pubitemid 28114643)
30. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England Journal of Medicine 2003; 349(25): 2387-2398.
31. Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology 2010; 57(1): 123-131.
32. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60(3): 434-441. (Pubitemid 35292169)
33. Damber JE. Endocrine therapy for prostate cancer. Acta Oncologica 2005; 44(6): 605-609.
34. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International 2008; 102(11): 1531-1538.
35. Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95(2): 361-376.
36. Schmitt B, Bennett C, Seidenfeld J et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 2000; (2): CD001526.
37. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. European Urology 2010; 57(1): 49-59.
38. Huggins C. Effect of orchidectomy and irradiation on cancer of the prostate. Annals of Surgery 1942; 115(6): 1192-1200.
39. Huggins CH & Hodges CV. Studies on prostate cancer. 1 The effect of castration, of estrogens and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Research 1941; 1: 293-297.
40. Tombal B. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urologia Internationalis 2009; 83(4): 373-378.
41. Thomas LN, Lazier CB, Gupta R et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. The Prostate 2005; 63(3): 231-239. (Pubitemid 40571057)
42. Biancolella M, Valentini A, Minella D et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Investigational New Drugs 2007; 25(5): 491-497. (Pubitemid 47222914)
43. Miyata Y, Kanda S, Sakai H et al. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment. Urology 2005; 65(6): 1238-1243. (Pubitemid 40824938)
44. Andriole G, Lieber M, Smith J et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995; 45(3): 491-497.
45. Fleshner NE & Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. The Journal of Urology 1995; 154(5): 1642-1645 [discussion 1645-6].
46. Brufsky A, Fontaine-Rothe P, Berlane K et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49(6): 913-920. (Pubitemid 27246962)
47. Ornstein DK, Rao GS, Johnson B et al. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48(6): 901-905. (Pubitemid 26427098)
48. Tay MH, Kaufman DS, Regan MM et al. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals of Oncology 2004; 15(6): 974-978. (Pubitemid 39004356)
49. Barqawi AB, Moul JW, Ziada A et al. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003; 62(5): 872-876. (Pubitemid 37421234)
50. Kirby R, Robertson C, Turkes A et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International prostate health council (IPHC) trial study group. The Prostate 1999; 40(2): 105-114. (Pubitemid 29304701)
51. Hsing AW. Hormones and prostate cancer: what's next? Epidemiologic Reviews 2001; 23(1): 42-58.
52. Platz EA & Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 2004; 92(4): 237-253. (Pubitemid 40128245)
53. Roddam AW, Allen NE, Appleby P et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 2008; 100(3): 170-183.
54. Lindstrom S, Ma J, Altshuler D et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the national cancer institute breast and prostate cancer cohort consortium. The Journal of Clinical Endocrinology and Metabolism 2010.
55. Dobs AS & Morgentaler A. Does testosterone therapy increase the risk of prostate cancer? Endocrine Practice 2008; 14 (7): 904-911.
56. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. The Journal of Urology 2009; 181(3): 972-979.
57. Imperato-McGinley J & Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Molecular and Cellular Endocrinology 2002; 198(1-2): 51-59. (Pubitemid 36169934)
58. Tindall DJ & Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. The Journal of Urology 2008; 179(4): 1235-1242.
59. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine 2003; 349(3): 215-224.
60. Andriole G, Bostwick D, Civantos F et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. The Journal of Urology 2005; 174(6): 2098-2104. (Pubitemid 41611745)
61. Cussenot O, Azzouzi AR, Nicoliew N et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. European Urology 2007; 52(4): 1082-1087.
62. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. The New England Journal of Medicine 2010; 362(13): 1192-1202.
63. Hofland J, van Weerden WM, Dits NF et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Research 2010; 70(3): 1256-1264.
64. Mostaghel EA, Geng L, Holcomb I et al. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Research 2010; 70(4): 1286-1295.
65. Cunha GR, Chung LW, Shannon JM et al. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Progress in Hormone Research 1983; 39: 559-598.
66. Wu CT, Altuwaijri S, Ricke WA et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 2007; 104(31): 12679-12684. (Pubitemid 47255214)
67. Franck-Lissbrant I, Haggstrom S, Damber JE et al. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139(2): 451-456. (Pubitemid 28513188)
68. Shabisgh A, Tanji N, D'Agati V et al. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999; 140(4): 1920-1926. (Pubitemid 29149266)
69. Stewart RJ, Panigrahy RJ, Flynn E et al. Vascular endothelial growth factor expression and tumour angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. The Journal of Urology 2001; 165(2): 688-693. (Pubitemid 32060501)
70. Halin S, Hammarsten P, Wikstrom P et al. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. The Prostate 2007; 67(4): 370-377. (Pubitemid 46341077)
71. Laitinen S, Martikainen PM, Tammela TL et al. Cellular changes in prostate cancer cells induced by intermittent androgen suppression. European Urology 2007; 52(3): 725-732. (Pubitemid 47126127)
72. Ohlson N, Wikstrom P, Stattin P et al. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. The Prostate 2005; 62(4): 307-315. (Pubitemid 40224136)
73. Westin P, Stattin P, Damber JE et al. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. The American Journal of Pathology 1995; 146(6): 1368-1375.
74. Wikstrom P,Westin P, Stattin P et al. Early castration-induced up regulation of transforming growth factor beta1 and its receptors is associated with tumour cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. The Prostate 1999; 38(4): 268-277. (Pubitemid 29119792)
75. Gustavsson H, Welen K & Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. The Prostate 2005; 62(4): 364-373. (Pubitemid 40227488)
76. Denmeade SR, Jakobsen CM, Jansson S et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute 2003; 95(13): 990-1000. (Pubitemid 36896716)
77. Joly-Pharaboz MO, Kalach JJ, Pharaboz J et al. Androgen inhibits the growth of carcinoma cell lines established from prostate cancer xenografts that escape androgen treatment. The Journal of Steroid Biochemistry and Molecular Biology 2008; 111(1-2): 50-59.
78. Morgentaler A, Bruning 3rd CO & DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276(23): 1904-1906. (Pubitemid 26419188)
79. Morgentaler A & Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006; 68(6): 1263-1267. (Pubitemid 44880344)
80. Morley JE, Kaiser FE, Perry 3rd HM et al. Longitudinal changes in testosterone, luteinizing hormone, and folliclestimulating hormone in healthy older men. Metabolism 1997; 46(4): 410-413. (Pubitemid 27172090)
81. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. The Journal of Clinical Endocrinology and Metabolism 2001; 86(2): 724-731. (Pubitemid 32207487)
82. Algarte-Genin M, Cussenot O & Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. European Urology 2004; 46(3): 285-294 [discussion 294-5].
83. Zhang PL, Rosen S, Veeramachaneni R et al. Association between prostate cancer and serum testosterone levels. The Prostate 2002; 53(3): 179-182. (Pubitemid 35266177)
84. Linja MJ, Savinainen KJ, Saramaki OR et al. Amplification and overexpression of androgen receptor gene in hormonerefractory prostate cancer. Cancer Research 2001; 61(9): 3550-3555. (Pubitemid 32694958)
85. Gregory CW, Hamil KG, Kim D et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 1998; 58(24): 5718-5724. (Pubitemid 29006412)
86. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995; 9(4): 401-406.
87. Newmark JR, Hardy DO, Tonb DC et al. Androgen receptor gene mutations in human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 1992; 89(14): 6319-6323.
88. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. The New England Journal of Medicine 1995; 332(21): 1393-1398.
89. Gregory CW, Johnson Jr. RT, Mohler JL et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 2001; 61(7): 2892-2898. (Pubitemid 32691931)
90. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 2001; 61(11): 4315-4319. (Pubitemid 32685750)
91. Titus MA, Schell MJ, Lih FB et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 2005; 11(13): 4653-4657. (Pubitemid 41557182)
92. Mohler JL, Gregory CW, Ford 3rd OH et al. The androgen axis in recurrent prostate cancer. Clinical Cancer Research 2004; 10(2): 440-448. (Pubitemid 38173980)
93. Stanbrough M et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 2006; 66(5): 2815-2825.
94. Ryan CJ, SMith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology 2010; 28(9): 1481-1488.
95. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology 2010; 28(9): 1496-1501.
96. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of Clinical Oncology 2010; 28(9): 1489-1495.
97. Taylor CD, Elson P & Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. Journal of Clinical Oncology 1993; 11(11): 2167-2172. (Pubitemid 23332253)
98. Tomita K, van Bokhoven A, van Leenders GJ et al. Cadherin switching in human prostate cancer progression. Cancer Research 2000; 60(13): 3650-3654. (Pubitemid 30482189)
99. Gravdal K, Halvorsen OJ, Haukaas SA et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Research 2007; 13(23): 7003-7011. (Pubitemid 350276881)
100. Jennbacken K, Tesan T, Wang W et al. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocrine-Related Cancer 2010; 17(2): 469-479.
101. Kleeberger W, Bova GS, Nielsen ME et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Research 2007; 67(19): 9199-9206. (Pubitemid 47535906)
102. Miyamoto H, Altuwaijri S, Cai Y et al. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Molecular Carcinogenesis 2005; 44(1): 1-10. (Pubitemid 41216402)
103. Li J, Wang E, Rinaldo F et al. Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 2005; 24(35): 5510-5520. (Pubitemid 43080094)
104. Lee YC, Cheng CJ, Huang M et al. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. The Journal of Pathology 2010.
105. Wei Q, Li M, Fu X et al. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer and Prostatic Diseases 2007; 10(2): 167-174. (Pubitemid 46887067)
106. Best CJ, Gillespie JW, Yi Y et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research 2005; 11(19 Pt 1): 6823-6834. (Pubitemid 41428737)
107. Holzbeierlein J, Lal P, LaTulippe E et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. The American Journal of Pathology 2004; 164(1): 217-227. (Pubitemid 38364606)
108. Tamura K, Furihata M, Tsunoda T et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Research 2007; 67(11): 5117-5125. (Pubitemid 46997247)
109. Niu Y, Altuwaijri S, Lai KP et al. Androgen receptor is a tumour suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(34): 12182-12187.
110. Niu Y, Altuwaijri S, Yeh S et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(34): 12188-12193.
111. Hara T, Miyazaki H, Lee A et al. Androgen receptor and invasion in prostate cancer. Cancer Research 2008; 68(4): 1128-1135. (Pubitemid 351272231)
112. Kanai M, Ishii K, Kanda H et al. Improvement in predicting tumourigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme. Cancer Science 2008; 99 (12): 2435-2443.
113. Olapade-Olaopa EO, MacKay EH, Taub NA et al. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clinical Cancer Research 1999; 5(3): 569-576. (Pubitemid 29131966)
114. Henshall SM, Quinn DI, Lee CS et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Research 2001; 61(2): 423-427. (Pubitemid 32128590)